Josep Quer Sivila I am a senior researcher at VHIR, specializing in Virology. Since 1989, I have focused my studies on research regarding the infection by the Hepatitis C virus (HCV), with a special emphasis on viral diversity. In 1992, I participated in the first description of the quasispecies nature of HCV. Since 2010, our research has been centred on the use of next-generation sequencing (NGS) platforms to study the diversity of viral genomes, especially viral hepatitis (A, B, C, D, and E). We have successfully patented and implemented into routine diagnosis a method for subtype classification and another for reporting resistances to antiviral treatments against HCV. The complete sequencing of SARS-CoV-2 in March 2020 has allowed us to monitor the tracking variations in defective genomes in the variants that have dominated each wave of SARS-CoV-2. Currently, we are developing bioinformatic pipelines for metagenomic studies. Instituciones de las que forman parte Investigador/a principal Enfermedades Hepáticas Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Email Josep Quer Sivila LinkedIn Twitter Orcid Email Instituciones de las que forman parte Investigador/a principal Enfermedades Hepáticas Vall Hebron Institut de Recerca I am a senior researcher at VHIR, specializing in Virology. Since 1989, I have focused my studies on research regarding the infection by the Hepatitis C virus (HCV), with a special emphasis on viral diversity. In 1992, I participated in the first description of the quasispecies nature of HCV. Since 2010, our research has been centred on the use of next-generation sequencing (NGS) platforms to study the diversity of viral genomes, especially viral hepatitis (A, B, C, D, and E). We have successfully patented and implemented into routine diagnosis a method for subtype classification and another for reporting resistances to antiviral treatments against HCV. The complete sequencing of SARS-CoV-2 in March 2020 has allowed us to monitor the tracking variations in defective genomes in the variants that have dominated each wave of SARS-CoV-2. Currently, we are developing bioinformatic pipelines for metagenomic studies.
Senior Researcher at Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus from 2021 (indefinite contract). Associate Professor at the Biochemistry and Molecular Department of the UAB from 2021 to present (3933001435 Y0LOU0146). Accredited researcher at CIBERehd (2010-prest). Accredited as Professor (Catedrático) from AQU (Generalitat de Catalunya) from 2023. Academic background: Bachelor in Biology from UB (1981-86). PhD in Biology from UAB (1994) with extraordinary award. Postdoctoral stay in the University of California at San Diego USA (1994-96). Member of Ciberehd since 2007-act. Associate Professor (AP) of Immunology, UB (1988-89); AP Medicine, UAB (2003-18); AP of Biochemistry and Molecular Biology, UAB (2021-pres.). General Coordinator Master in "Translational Biomedical Research" VHIR-UAB (2020-pres.). Professor and coordinator of Module 1 Master in "Translational Biomedical Research" VHIR-UAB since 2014-pres. Scientific and professional activities: Projects: Since 2016, he has led 10 overlapping competitive financed projects, serving as the Principal Investigator (PI) in eight national projects and as the co-IP of the local-node in two European Union projects. Thesis: 6 PhD thesis directed, and 3 under development. Papers and reviews: 154 papers; 8 book chapters & 1 book published in 2023. Meetings participation: 220, 66 of them as invited speaker. Other merits: Member Coordinator Committee “Strategic Plan for Tackling hepatitis C (PEAHC) Spanish Ministry of Health; Treasurer Spanish Society of Virology (SEV) (2009-pres.); Member of scientific societies (ESV;AEEH;SCB) and of Alliance for the Elimination of Hepatitis in Spain (AEHVE). Organizing Committee of International Symposium Fundación Ramón Areces (2013); and SEV National Meetings (2013-2015-2017-2019-2022). Impacts printed, digital, radio and TV. NGS-2010: 32 impacts; HCV-2015: 69 impacts; SARS-CoV-2 – 2020-23: 90 impacts. Awards: Ciudad de Barcelona (1996); Best ideas Diario Medico (2015); Premi Ciència i Tecnologia Diari Regió7-Prensa Ibérica (2020). Metrics: h-index:41 (scholar), 35 (WoS), 37 (Scopus); i10-index: 116; Citations (WoS): 8371; Views: >40000. ORCID: 0000-0003-0014-084X // WOS ResearcherID A-6741-2012 // SCOPUS ID: 7004592398 Social media: Linkedin: Josep Quer Twitter (X): @JosepQuerSivila / @VirusLabQ (Virus Lab by Dr. Josep Quer) / @HepatitisSEV
Proyectos Estudio alegorizado de dos estrategias de tratamiento con Ribavirina para la Hepatitis Crónica E y formas agudas graves. IP: Rafael Esteban Mur Colaboradores: Maria del Mar Riveiro Barciela, Francisco Rodríguez Frias, Josep Quer Sivila, Basilio Rodriguez Diez, Cristina Berastegui Garcia, Virginia Robles Alonso Entidad financiadora: Instituto de Salud Carlos III Financiación: 261360 Referencia: ICI14/00367 Duración: 01/01/2015 - 30/06/2019 Malalties Hepatobiliars (GRC) IP: Rafael Esteban Mur Colaboradores: Beatriz Minguez Rosique, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Antonio González Fernández, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Francisco Rodríguez Frias, Silvia Sauleda Oliveras, Victor Manuel Vargas Blasco, Maria Buti Ferret, Torrens Buscató, Maria Margarita, Josep Quer Sivila, Josep Gregori Font, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Juan Ignacio Esteban Mur, Meritxell Ventura Cots, Macarena Simon-Talero Horga, Joan Genescà Ferrer, David Tabernero Caellas Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca Financiación: 65000 Referencia: 2014 SGR 421 Duración: 01/01/2014 - 31/12/2016 Aplicación de la tecnología de secuenciación masiva para optimizar el coste-efectividad del tratamiento de la hepatitis C (VHC) en la era de los inhibidores de acción directa (DAAs). IP: Juan Ignacio Esteban Mur Colaboradores: Lluís Viladomiu Catà, Lluis Castells Fusté, Josep Quer Sivila, Damir Garcia Cehic, Cristina Dopazo Taboada Entidad financiadora: Instituto de Salud Carlos III Financiación: 192692.5 Referencia: PI13/00456 Duración: 01/01/2014 - 31/01/2017 Estudio dinámico de quasispecies de VHC por pirosecuenciación en fase aguda y crónica durante tratamiento antiviral (PIROVIRUSC) IP: Josep Quer Sivila Colaboradores: Itxarone Izaskun Bilbao Aguirre, Lluis Castells Fusté Entidad financiadora: Ministerio de Ciencia e Innovación-MICINN Financiación: 121000 Referencia: SAF2009-10403 Duración: 01/01/2010 - 31/12/2012 Paginación Primera página « Página anterior ‹ … Página 2 Página 3 Página actual 4 Página 5 Página 6 … Siguiente página › Última página »
